Brand name: Trodelvy
Chemical name: Sacituzumab govitecan-hziy
Class: Antibody-drug conjugate immune targeted therapy. Trodelvy is made up of:
- sacituzumab, a type of protein called a monoclonal antibody, that targets the Trop-2 protein; the Trop-2 protein is found in more than 90% of triple-negative breast cancers
- SN-38, a topoisomerase I inhibitor chemotherapy; topoisomerase I inhibitors work by interfering with the cancer cells’ ability to replicate
- a compound that links the sacituzumab to the SN-38
The linking compound attaches (conjugates) the monoclonal antibody sacituzumab to the SN-38 chemotherapy.
Uses: Trodelvy is used to treat adults diagnosed with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more systemic therapies (such as chemotherapy or targeted therapy), at least one of which was for advanced-stage disease.
How it’s given: Trodelvy is given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or port.
- low white blood cell counts
- hair loss
- decreased appetite
- abdominal pain
Read more about Trodelvy.
- Trodelvy (sacituzumab govitecan-hziy) prescribing information. Immunomedics, 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf (PDF)
- U.S. Food and Drug Administration. “FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.” April 7, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
What Is Breast Implant Illness?
Breast implant illness (BII) is a term that some women and doctors use to refer to a wide range...